After trial success, Alnylam plans to seek FDA approval for 2nd drug
March 06, 2019 at 08:20 AM EST
The company announced Wednesday that its drug givosiran met its primary endpoints in a Phase 3 trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|